Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer

Xiang Zheng*, Qiu Peng*, Lujuan Wang*, Xuemei Zhang2, Lili Huang1, Jia Wang3, Zailong Qin1*  
1. Laboratory of Genetics and Metabolism, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region; Guangxi Birth Defects Research and Prevention Institute, Nanning, Guangxi, 530003, China.  
2. Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541001, China.  
3. Department of Immunology, Changzhi Medical College, Changzhi, Shanxi, 046000 China.  
4. Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, Hunan, 410008, China.  
*These authors contributed equally to this study.
splicing [11]. Extensive evidence has proved that SRs are involved in nearly every step of spliceosome assembly [12]. In addition, SRs have also been demonstrated to be associated with genomic stability, mRNA export, mRNA stability and translation [13, 14].

SRs, the important splicing regulators, belong to the serine arginine-rich protein family and canonically consisted of 12 members (SRSF1-12) [15]. The first SRs identified were SRSF1 (previously called SF2/ASF) and SRSF2 (previously called SC35) [16]. Most SRs are located exclusively in the nucleus, but some SRs (such as SRSF1, SRSF3 and SRSF7) can shuttle between nucleus and cytoplasm [17]. Because SRs play a pivotal role in transcription and translation, dysregulation of SRs greatly disrupts both DNA stability and normal protein expression pattern, then leads to abnormal biological function. Recently, it has been widely studied that SRs act as oncoproteins in various tumor types, such as lung, colon, breast, pancreas and leukemia cancer [18-21]. In this review, we summarized the function and mechanism of SRs in RNA splicing and their roles in tumor progression. We also discussed the role of SRs as potential therapeutic targets for cancer therapy.

Structure and Function of SRs

Structure of SRs

SRs are serine/arginine-rich splicing factors which are very conserved in plants and animals [22, 23]. The SRs were first discovered in the early 1990s as the essential splicing factors that influenced alternative splicing in Hela cells [24, 25]. SRs consist of 12 members in mammalian (SRSF1-12), which have the very similar domains. SRs are characterized by the presence of an N-terminal 1 or 2 RNA recognition domains (RRM domain) and a C-terminal domain enriched with the Arginine (R) and Serine (S) amino acid sequences (RS domain) [26] (Fig. 1). In general, RRM domains recognize RNA and determine the binding of SRs to RNA, while RS domains mediate diverse protein-protein and protein-RNA interactions regulated by phosphorylation [16].

Function of SRs

Function of SRs in alternative pre-mRNA splicing

SRs commonly designate a family of RNA binding proteins that share common RNA binding motifs [15]. The unique RS domain is an important structure that distinguishes SRs from other RNA-binding proteins. As the ubiquitous splicing factors, SRs play an important role in both constitutive and alternative splicing functions. In the splicing reaction, the SRs bind to exonic splicing enhancers (ESE), recruit small nuclear ribonucleoprotein (snRNP) and its cofactors to the splicing sites [27]. Next, SRs facilitate the U2 small nuclear RNA binding to the branch point region of pre-mRNA to form complex A, and then they also bridge the communication between these initial splice site recognition events in the

![Figure 1. List and domain structures of SRs](http://www.ijbs.com)
pre-spliceosome and the mature spliceosome to form a bridge complex across the splicing sites by binding to U2AF and U1 70K, thereby promoting the recruitment of U4/U5/U6 snRNP to form complex B [28] (Fig. 2). In addition, the locations of SRs in pre-mRNA sites affect the splicing outcome. For example, exon-combined SRs act as enhancers, but intron-combined SRs may as suppressors [29]. Therefore, the location of SRs-pre-mRNA interactions affect the selection of splicing sites and the assembly of spliceosome [30].

Function of SRs in transcription

A large number of studies have found that SRs play a pivotal role in almost all processes of RNA metabolism. In addition to regulating RNA splicing, SRs also plays an important role in regulating transcription (Fig. 3) [31]. SRs are concentrated in nuclear speckles which are small subnuclear membraneless organelles or structures, also called the splicing factor compartments and are from there recruited to nascent transcripts transcribed by RNA polymerase II (Pol II) [32]. The interactions of SR-related proteins with the C-terminal domain of Pol II have been reported [33], and the SRs were also identified in the Pol II complex, which elucidates that SRs may contribute to transcriptional elongation [34]. Further studies show that SRSF2 could dynamically bridge P-TEFb to Pol II and thereby further catalyzes Pol II phosphorylation in C-terminal domain to promote transcriptional elongation in genes [35]. In addition, the co-transcriptional complex of SRs have been demonstrated to prevent the formation of R loops because of hybridization of the synthesized pre-mRNA to the complementary strand of the DNA template and thus to contribute to genome stability [14].

Function of SRs in the splicing of transcripts containing N6-methyladenosine (m6A) modifications.

N6-methyladenosine (m6A) is the most prevalent internal RNA modification, especially within eukaryotic messenger RNAs (mRNAs), affecting various aspects of biological processes including RNA splicing (Fig. 4) [36]. m6A modifications are catalyzed by RNA methyltransferases, such as METTL3, METTL14 and WTAP (writers). The modifications are removed by the demethylases fat mass and obesity associated protein (FTO) and ALKB homolog 5 (ALKBH5) (erasers). The modifications are recognized by m6A-binding proteins, such as YTH domain-containing proteins and IGF2BPs (readers) [37]. Disruption of the dynamic of m6A can affect the levels of many RNAs, because the methylation-related molecules are located in nuclear speckles and interact with splicing factors which may be involved in modulating splicing [38]. Recent studies indicate that the downregulation of ALKBH5 can affect the...
distribution of splicing factors, such as SRSF1, SRSF2 and SRPK1 [39]. FTO could mediate splicing of RUNX1 through recruiting SRSF2 [40]. Xiao et al. reported that YTHDC1 promotes exon inclusion in targeted mRNAs through recruiting pre-mRNA splicing factor SRSF3 while blocking SRSF10 bound to the region near the m6A sites, ultimately resulting in exon skipping owing to the failure of m6A modification [41]. Feng Z et al. also showed that METTL3 knockdown facilitates the formation of MyD88 isoform through regulating splicing [42].

Role of SRs Family in Cancer

Almost all tumors have complex pathogenesis with the participation of multiple factors. The above-mentioned studies provide enough evidence to support the correlation between SRs and cancers. Because SRs are the master regulator of pre-mRNA splicing, dysregulation of SRs greatly damage DNA stability and normal expression pattern of protein, and then result in aberrant biological function, which indicates a critical role for SRs in cancer. For example, Li et al found that depletion of SRSF1 in vivo could induce DNA double-strand break and gross DNA recombination [14]. Similarly, Xiao et al also showed that loss of SRSF2 in mouse embryo fibroblasts induced double strand break and G2/M cell cycle arrest via regulating at least in part the p53 hyper-phosphorylation and hyperacetylation [43]. Indeed, a series of experiments have demonstrated that SRs are aberrantly expressed in human cancers, participating in tumorigenesis and cancer metastasis (Fig. 5).

Abnormal expression of SRs and cancer

Growing evidence establish the relationship between the dysregulated expression of SRs and tumorigenesis which mainly owing to changing in the alternative splicing patterns of key genes. It has been reported that copy number of SRs are dramatically increased in various cancers, which are related to the high expression of SRs in cancers [18]. For example, SRSF6 has been found to be massively amplified in lung, colon and breast cancers [44]. Using both discovery and validation patient cohorts, Jiang L et al. reported that SRSF1 DNA copy number gain and mRNA over-expression were strongly associated with poor survival, and they further demonstrated that SRSF1 is important for tumorigenesis of SCLC (small cell lung cancer) and may play a key role in DNA repair and chemo-sensitivity both in vitro and in vivo. Moreover, SRSF1 promotes SCLC growth and survival by regulating PI3K/AKT and MEK/ERK signaling pathways, which are well-known as oncogenic signaling pathways [21]. Increased expression of SRs usually correlate with cancer progression, as in malignant ovarian tissue, the expression of SRSF1, SRSF2 and SRSF3 were significantly upregulated relative to normal tissue [45]. Park WC et al. found that the expression of SRSF7 was higher in gastric cancer than normal gastric tissue [46]. Song et al also observed that the level of SRSF7 was upregulated in NSCLC tissues, meanwhile, the expression level of SRSF7 was negatively correlated with miR-374b-5p and positively correlated with MALAT1. Overexpression of SRSF7 could reverse the effects of MALAT1 knockdown on proliferation, apoptosis, and invasion in NSCLC cells [47]. In addition, SRSF1 was found to be upregulated in colon, kidney, lung, liver, pancreas and breast tumour [18, 20, 48, 49]. Kim et al reported that the expression level of SRSF5 was markedly up-regulated in lung cancer samples compared with normal lung tissue samples and SRSF5 showed the higher detection accuracy (89%) than carcino-embryonic antigen(74%)(CEA, a commonly marker of non-small cells lung cancer (NSCLC) [50]. Yang et al also discovered that SRSF5 is overexpressed in oral squamous cell carcinoma tissues and cells. The expression of SRSF5 is controlled by an autoregulation mechanism [51]. Fu et al demonstrated that SRSF9 is frequently overexpressed in many types of tumors through immunohistochemistry staining, such as glioblastoma, colon adenocarcinoma, squamous cell lung carcinoma and malignant melanoma [52]. Other SRs, such as SRSF3, SRSF5 and SRSF6 also presented a higher expression level in colorectal cancer than normal tissue [46].
Figure 4. SRs affects the splicing of transcripts containing N6-methyladenosine (m6A) modifications. m6A methylation of RNA is catalyzed by the methyltransferase METTL3 and METTL14. YTHDC1 could effectively binds to m6A site and recruit SRSF3 to pre-mRNA, leading to exon inclusion. If fat mass and obesity-associated (FTO) demethylates the m6A site, as a result, SRSF10 instead of SRSF2 binds to pre-mRNA, leading to exon skipping.

Figure 5. Role of SRs family in cancer. The diagram shows selected examples of genes with cancer-related alternatively spliced isoforms that due to the activity of specific SRs. Red arrowheads represent promotion and green lines represent inhibition.

Abnormal expression of SRs often causes changes of cancer-related processes, such as epithelial-mesenchymal transition, metastasis and angiogenesis. Kong et al identified that SRSF6 promoted the EMT and metastasis in colorectal cancer, and found that the knockdown of SRSF6 significantly increased the expression of E-cadherin as well as reduced the expression of Snail, Vimentin, Fibronectin and MMP9 in SW620 cells [53]. In addition, Wan et al also found that SRSF6 could...
promote invasion and metastasis in colorectal cancer by inhibiting ZO-1 exon23 inclusion, which known to play an inhibitory role in colorectal cancer progression [54]. Recently, Zhou et al reported that SRSF1 is increased in glioma tissues and cell lines. Moreover, Further studies revealed that SRSF1-mediated splicing of the MYO1B increased the potential of proliferation, and metastasis in glioma cells by regulating the PDK1/ AKT and PAK/LIMK pathway [55]. Angiogenesis is modulated by the balance of pro-angiogenic VEGF165 and anti-angiogenic VEGF165b splicing isoforms. Manetti et al demonstrated that SRSF6 could involve in distal splice-site selection as it bound around the distal splice-site and was up-regulated by TGFβ, resulting in increased expression of VEGF165b and inhibition of angiogenesis [56].

Table 1. Dysregulated SRs’ expression in cancer

| SRs     | Cancer Type               | Target Gene                  | Effects on Cancer Progression | References |
|---------|---------------------------|------------------------------|-------------------------------|------------|
| SRSF1   | Breast, Lung, and Colon cancer | Cyclin D1, CASP9, B1, Mnk2 and RON1 | Cell proliferation, invasion, migration and apoptosis | [63, 65] |
| SRSF2   | Lung and renal cancer     | Caspase-8, BCL-x, MCL-1, Survivin and BIM | Apoptosis                      | [136, 137] |
| SRSF3   | Breast cancer             | MCL-1                        | Apoptosis                      | [66]       |
| SRSF4   | Acute Myeloid Leukemia    | Caspase-8                    | Apoptosis                      | [19]       |
| SRSF5   | Breast cancer             | MCL-1                        | Apoptosis                      | [66]       |
| SRSF6   | Melanoma                  | BIM                          | Apoptosis                      | [138]      |
| SRSF7   | Colon and lung cancer     | Fas                          | Apoptosis                      | [47]       |
| SRSF9   | Colon cancer              | b-catenin                    | Proliferation                  | [52]       |
| SRSF10  | Colon cancer              | BCLAF1                       | Apoptosis                      | [73]       |

Splicing function of SRs and cancer

Most genes undergo alternative splicing, and the isoforms produced by alternative splicing are closely related to the progression and metastasis of cancers [57], such as pro-oncogenic and antiapoptotic splicing isoforms of MDM2, BCL(X), and VEGF genes [58]. In tumor cells, SRs cause abnormal splicing of many tumor-related genes, which affect cell proliferation, apoptosis and migration, and thereby promotes tumorigenesis and cancer development [59, 60]. Karni R et al. found that upregulated SRSF1 protein increased the splice isoform of BIN1 (bridging integrator-1). The resulting BIN1 isoforms cannot bind to the oncoprotein MYC, causing the BIN1 protein to lack tumor-suppressor activity [18]. A series of studies found that dysregulated expression of SRSF1 protein can also alter alternative splicing of many other tumor-related genes. For example, in prostate cancer, SRSF1 promotes the increase of oncogenic cyclin D1b splice isoform [61]. In lung cancer, SRSF1 promotes the expression of the anti-apoptotic caspase 9b splice isoform [62]. In breast cancer, SRSF1 regulates the alternative splicing of the pro-apoptotic gene BIM, which increases the expression of splice variant lacking the BH3 domain, thereby inhibiting apoptosis [63]. In addition, the alternative splicing regulated by SRSF1 in tumor cells also includes the proto-oncogenes MYBL2 (B-myb), MYB (C-myb) [64], the tumor suppressor gene BRCA1 [65], and the apoptosis-related gene McIl [66], Vascular endothelial growth factor VEGF [67], cell migration-related gene MST1R (Ron) [49], etc. In addition, Kurokawa K et al. found that SRSF3 can regulate apoptosis by affecting alternative splicing of HIPK2 (homeodomain-interacting protein kinase-2) and produced a HIPK2 Δe8 isoform in colon cancer cells [68]. Liu et al found that compared with control, the expression of SRSF4 was obviously decreased in Acute Myeloid Leukemia (AML) patients. Moreover, an important correlation was observed between SRSF4 and the caspase-8 splicing isoforms in AML patients [19]. Shi J et al. reported that SRSF2 involved in the regulation of alternative splicing of the tumor suppressor gene KLF6 (Krüppel-like factor 6) and promoted the production of splice isoform containing KLF6 exon 1a. The isoform of KLF6 which cannot inhibit tumorigenesis due to the absence of the DNA binding domain [69]. SRSF6 can regulate the alternative splicing of tumor-related genes, such as the insulin receptor INSR, the kinase Mnk2 (MKNK2) and the tumor suppressor gene DLG-1, thereby mediating tumorigenesis [70-72]. Zhou X et al. showed that SRSF10 was up-regulated in colon cancer samples, and inhibition of SRSF10 could significantly inhibit the proliferation and tumorigenesis in colon cancer cells by regulating the expression of Bcl-2-associated transcription factor 1 (BCLAF1) isoform containing BCLAF1 exon5a [73]. Recently, Liu et al showed that SRSF10, was upregulated by human papillomavirus oncoproteins E6 and E7 through E2F1 pathway, and promoted the tumorigenesis of cervix. Further investigation that SRSF10 could promote the expression of CD47 to inhibit macrophage phagocytosis by promoting nuclear factor-κB activation by regulating the splicing of interleukin-1 receptor accessory protein exon 13.

Recent genome-wide analyses of cancer have revealed globally abnormal splicing profiles in mature mRNA [74, 75]. The molecular mechanisms of aberrant splicing in cancers may be mutations in SRs, such as SRSF2 [76]. SRSF2 mutation is found in 40%-50% of patients in chronic myelomonocytic leukaemia [77]. SRSF2 missense mutation are highly concentrate on at residue P95 or to a lesser extent at
the surrounding residues (G93 to P107) [78]. SRSF2 canonically binds to C- and G-rich exonic splicing enhancers (ESEs) motifs to promote splicing [79]. The mutant SRSF2 preferentially recognizes C-rich CCNG ESE motif versus G-rich GGNG ESE motif and results in alternatively splicing of many mRNAs [80]. For example, Papaemmanuil et al reported that SRSF2 mutations altered the splicing of EZH2 mRNA that induced an in-frame stop codon in myeloid neoplasms. The abnormal EZH2 mRNA induces nonsense-mediated decay (NMD) and leads to the downregulation of EZH2 protein and histone H3 lysine 27 trimethylation levels [81].

**Translation function of SRs and cancer**

We mentioned above that the nuclear shuttle SR proteins can directly regulate mRNA translation [82]. Sanford JR et al. reported that SRSF1 could stimulate translation both *in vitro* using a HeLa cell-free translation system and in xenopus oocytes system [83]. As an adaptor protein, SRSF1 recruits mTORC1 or PP2A to its bound mRNA, and increases the phosphorylation level of 4E-BP1. Phosphorylated 4E-BP1 no longer binds to the initiation factor eIF4E, which promotes mRNA translation initiation [84]. Kashi R et al. have found that overexpression of SRSF1 could activate the mTORC1 signaling pathway, resulting in increased phosphorylation of its downstream target proteins S6K and 4E-BP1, and that the tumorigenesis of SRSF1 can be inhibited by the mTOR-specific inhibitor rapamycin [85]. Moreover, SRSF1 can activate the Ras-MAPK signaling pathway and increase cell transformation by increasing B-Raf expression [86]. Maslon MM et al. also performed a high-throughput deep sequencing analysis of polysomal fractions in cells overexpressing SRSF1 and identified approximately 1,500 mRNAs that were translational targets of SRSF1. These include mRNAs encoding proteins involved in cell cycle regulation, such as spindle, kinetochore and M phase proteins, which are essential for accurate chromosome segregation [87]. These findings suggest that the regulation of translational functions of the SRSF1 protein promotes, to a certain extent, SRSF1 protein-mediated cell transformation and tumorigenesis. Other shuttling SR proteins like SRSF7 and SRSF3 also have the function of regulating translation [88, 89]. For example, SRSF3 was reported to involve in the regulation of IRES (internal ribosomal entry site)-mediated translation initiation. Further investigation found that SRSF3 interacted with the RNA binding protein PCBP2 that bound to IRES sequences in the genomic RNAs of viruses and was necessary for viral translation. [88].

**Post-translational modification of SRs and cancer**

At least five types of posttranscriptional modifications are known in SRs, including methylation, acetylation, small ubiquitin-related modifier (SUMO), ubiquitination and phosphorylation [22]. There has been considerable interest in modulating splicing by modifying post-translational modifications (PTM) required for spliceosome function, and known that PTMs of a variety of splicing factors regulate spliceosome formation and splicing catalysis [90]. Arginine methylation has been detected on many RNA binding proteins, such as hnRNPs and SRs [91]. Arginine methylation in SRs was first reported on Npl3p in budding yeast [92]. In addition, Sinha R et al. reported that three methylated arginine residues were identified between the two RRMs in SRSF1, which appeared to play an important role in promoting nuclear import of the SRs. Further studies showed that arginine control the subcellular localization and the positive charge state. Mutations or block methylation and remove the positive charge lead to the cytoplasmic accumulation of SRSF1 [93]. Botti et al. also showed that arginine methylation in SRSF5 is important for its shuttling capacity and mRNA export [94]. Ubiquitin proteasome pathway-mediated protein degradation is an important mechanism by which the cell regulates intracellular protein levels and functions. Vaishali et al reported that ubiquitination can regulate the expression of SRSF1 in normal and T cells [95]. In addition, Osman et al showed that SRSF5 protein is decreased drastically during cell differentiation by proteasome-mediated proteolysis [96]. Chen et al also showed that mutually exclusive ubiquitylation and acetylation of SRSF5 control tumor growth by regulating the alternative splicing of CCAR1 to generate the CCAR1S isoform, which promote tumor growth by promoting glucose consumption and acetyl-CoA production [97]. In addition, reversible phosphorylation in the splicing reaction was necessary. Phosphorylation of SRs modulates the shuttling of SRs to modulate splicing. Phosphorylation of SRs is necessary for spliceosome assembly, but dephosphorylation of SRs allows splicing catalysis to occur and initiates nuclear export of SRs [28, 98, 99]. Phosphorylation of the RS repeat domain could release the stable α-helical structure to form the "arginine claw" structures which is recognized by a SRs specific transportin (TRN-SR), thereby trafficking the SRs to nucleus where it involves in splicing [100]. Serine-arginine protein kinase (SRPK) can phosphorylate Arg-Ser dipeptide repeats of SRs and promote nuclear import [101]. Abnormal expression of SRPK1 damages the
biological function of SRs, leading to aberrant splicing of pre-mRNA, which can contribute to the progression of cancers [102]. Matos et al reported that SRPK1 could regulate the alternative splicing of Rac1b that enhanced cell cycle progression via NF-kB signaling [103]. SRPK1 contributes to the splicing of Rac1b by inducing the phosphorylation of SRSF1 to further promote its entry into the nucleus [104]. Small ubiquitin-related modifier (SUMO) is a reversible and transient posttranslational protein modifier and involved in diverse biological processes, such as subcellular partitioning, transcription regulation, DNA damage repair, stress response and chromatin remodeling. Federico et al showed that the SRSF1 was a modulator of the sumoylation pathway. SRSF1 can enhance sumoylation of specific substrates by interacting with Ubc9. SRSF1 also can regulate SUMO E3 ligase protein inhibitor of activated STAT-1(Pias1)-induced overall protein sumoylation by interacting with the Pias1 [105]. In recent years, proteomic analysis has also shown extensive lysine acetylation in SRs, which may be an important nonhistone substrates recognized by histone acetyltransferases (HATs) in cells [106]. Edmond V et al. found that the acetyltransferase Tip60 acetylated SRSF2 on its lysine 52 residue inside the RNA recognition motif, thereby promoted its proteasomal degradation, while the deacetylase HDAC6 countered this acetylation and acted as a positive regulator of SRSF2 protein level [107].

**Other functions of SRs in cancer**

SRs regulate RNA metabolism at multiple levels. In addition to participating in the regulation of RNA splicing and translation efficiency, SRSF1 protein also plays a role in the nuclear export and stability of RNA. These functions may be involved in SRSF1-mediated tumorigenesis. For example, SRSF1 is highly expressed in non-small cell lung cancer. Down-regulating SRSF1 in non-small cell lung cancer cell lines can promote the occurrence of apoptosis, which is related to the down-regulation of anti-apoptotic protein survivin. Mechanism shows that SRSF1 specifically binds to survivin mRNA and regulates its expression at multiple levels. It not only relies on the mTOR signaling pathway to promote translation of survivin mRNA, but also stabilizes its mRNA level. The analysis of clinical tumor samples further confirms that there is a positive correlation between SRSF1 and survivin in non-small cell lung cancer. These results provide new data on the mTORC1- and survivin-dependent mechanisms of SRSF1-related carcinogenic potential, and suggest that the expression of SRSF1 and survivin is involved in NSCLC progression [108]. SRSF1 is also up-regulated in breast cancer. Overexpression of SRSF1 promotes cell transformation of breast epithelial cells both in vitro SRSF1-overexpressing MCF-10A cells and in vivo SRSF1-overexpressing COMMA-1D transplantation models, and promotes proliferation and inhibits apoptosis in three-dimensional culture cells, forming more acinar than normal cells [63]. Overexpression of SRSF1 in mammary epithelial cells not only regulates the alternative splicing of BIM and BIN1 to inhibit apoptosis, but also cooperates with the oncogene MYC to promote cell transformation [63]. Subsequent studies have further confirmed that MYC regulates its downstream splicing activity and tumorigenesis by promoting SRSF1 transcriptional activation [63].

**Role of SRs in Antitumor Therapies**

Because SRs play an important role in RNA metabolism, during the past decades, increasing strategies have been made to target the spliceosome for antitumor therapeutic approaches [109, 110]. As described above, it has been extensively reported that widespread changes in RNA splicing in cancer samples compared with normal samples, such as known pro-oncogenic and antiapoptotic isoforms of genes, including TP53, BCL (X), and VEGF [58, 111, 112]. Guyot et al. reported that anti-angiogenic forms of VEGF isoform VEGF165b can weaken the therapeutic effects of the anti-VEGF antibodies (bevacizumab/Avastin) in different tumor cell lines. [113]. These findings showed that regulating pre-RNA splicing of specific gene isoforms may serve as a new therapeutic strategy for cancer. Recently, a series of studies unveiled diverse compounds that targeted the spliceosome. Among the first compounds known to alter splicing are natural products (spliceostatin A, pladienolide B, and herboxidiene) that bind the SF3B complex [114, 115], and their derivatives including E7107 and H3B-8800 [116], which physically bind to the SF3B complex and inhibit pre-mRNA splicing at an early step in spliceosome assembly and thereby block splicing. In addition, Lee SC et al. showed that mutated SRSF2 are more sensitive to E7107 in comparison to cells bearing wild-type SRSF2 in leukemia, suggesting that cancers induced by spliceosome mutated factors was more sensitive to these drugs [117].

Chemo resistance and radioresistance are the major cause of cancer treatment failure. Splicing dysregulation plays key roles in tumorigenesis and the involvement of SRs in resistance of cancer to chemotherapy and radiotherapy remains elusive [118]. Recently, The expression level of SRSF1 was found increased in irradiation treated lung cancer cells, whereas interference of SRSF1 sensitized lung cancer cells to irradiation by regulating various
cancer-related splicing, such as the splicing of PTEN-like mitochondrial phosphatase (PTPMT1) [118]. Maude et al reported that SRSF4, but not SRSF6 played an important role in anti-cancer drug cisplatin affected splicing, and knockdown of SRSF4 expression inhibited lots of the splicing alterations and cell death induced by cisplatin [119].

Alternative splicing regulation is also a key target for anti-tumor treatment. SRs are phosphorylated by SRPK1 and SRPK2 (SRs kinases), DNA topoisomerase I and U4/U6 small ribonucleoprotein PRP4 [120]. Through regulation of SRs phosphorylation, small molecule inhibitors that target kinases involved in alternative splicing are promising candidates for drugs [121]. Pilch B et al. found that NB-506, an inhibitor of topoisomerase I, could inhibit the phosphorylation of SRSF1 and modulate gene expression by controlling splicing [122]. In addition, Wu F et al. reported that antibody targeting SRPK1, a key regulator of SRs phosphorylation, significantly inhibited the growth, migration and invasion of non-small cell lung cancer [123]. PRP4 belongs to the serine/threonine protein kinase family, plays an important role in cell mitosis and splicing. PRP4 kinase has been identified as a potential therapeutic target in multiple tumors. For example, Duan et al found that inhibition of PRP4 activity by shRNAs could reverse paclitaxel resistance 5-10-fold in human ovarian cancer [124]. Jouhua et al also showed that inhibition of PRP4 could enhance paclitaxel activity in breast cancer cells [125].

In another example, symmetric arginine dimethylation (SDMA), catalyzed by PRMT5, is required for spliceosome assembly [126, 127]. Some studies shown that compounds inhibition of PRMT5 results in splicing inhibition and anticancer effects in a number of cancer types [128, 129]. Recent studies positioned RNA methylation as a major pathway in modulating the development of tumor due to its function in post-transcriptional regulation including alternative splicing. It is of great significance to identify chemical inhibitors targeting m6A modification-related enzymes, including METTL3, METTL14, FTO and ALKBH5, etc [130].

Conclusions and Perspectives

Alternative splicing is a vital step in gene expression and generates transcriptome diversity in eukaryotic cells. As the key regulators of cellular biology, SRs are extensively participated in regulating from RNA stability to RNA splicing, and even RNA modification(m6A), export and translation [14, 84, 131]. Moreover, the expression of most SRs in various tumor types is up-regulated, and therefore SRs promotes tumorigenesis as proto-oncogenes. SRs mediate tumorigenesis mainly by regulating alternative splicing of tumor-related genes, providing a large number of targets for tumor prevention and treatment. Since most of the current research is focused on a single SR protein, this also leads to some interesting problems that have not been well explained. For example, do SRs regulated targets have something in common? are these targets regulated by many SR proteins or specifically by one? is the regulatory mechanism similar for all these targets? At present, it is known that antisense oligonucleotides or small molecule drugs can be used to regulate some alternative splicing processes that mediate tumorigenesis [132]. These may be one of the measures to achieve tumor treatment by targeting SRs in tumorigenesis. However, due to relatively few animal models system for knock-out/knock-in SRs, the regulation of SRs is still incomplete, and more research is needed in this area to further determine the functions and mechanisms of different SRs in tumorigenesis, which will provide more abundant research ideas and treatment strategies for tumor treatment. In addition, with the broad application of bioinformatics and high-throughput sequencing technology in research, increasing numbers mutations of SRs have been found in tumors. What specific role do these mutations play in the progression of tumors? And whether repairing these mutations can be used as a potential treatment strategy is still unknown. Of course, I believe that with the advancement of research methods, more and more mysteries about SRs will be unveiled.

Abbreviations

AS: Alternative splicing; m6A: N6-methyladenosine; RBP: RNA-binding protein; ESE: exonic splicing enhancer; ISE: intronic splicing enhancer; ESS: exonic splicing silencer; ISS: intronic silencer; RRM: RNA recognition; hnRNP: heterogeneous nuclear ribonucleoprotein; snRNP: small nuclear ribonucleoprotein; P-TEFb: The positive transcription elongation factor b; METTL3: Methyltransferase-Like Protein 3; METTL14: Methyltransferase-Like Protein 14; WTAP: Wilms Tumor 1 Associated Protein; FTO: Fat Mass and Obesity-Associated Protein; ALKBH5: Alpha-Ketoglutarate-Dependent Dioxygenase AlkB Homolog 5; YTHDF: YTH Domain-Containing Family Protein 1; IGF2BP: Insulin Like Growth Factor 2 MRNA Binding Protein; RUNX1: RUNX Family Transcription Factor 1; YTHDC1: YTH Domain-Containing Protein 1; SCLC: small cell lung cancer; BIN1: Bridging Integrator 1; MYC: MYC proto-oncogene; BIM: Bcl-2-Like Protein 11; MYBL2: MYB Proto-Oncogene Like 2; MYB: MYB Proto-Oncogene;
BRCA1: Breast Cancer Type 1 Susceptibility Protein; Mc11: Myeloid Cell Leukemia Sequence 1; VEGF: Vascular Endothelial Growth Factor; MST1R: Macrophage Stimulating 1 Receptor; HIPK2: Homeodomain Interacting Protein Kinase 2; KLF6: Kruppel Like Factor 6; INSR: Insulin Receptor; Mnk2: MAPK Interacting Serine/Threonine Kinase 2; DLG-1: Discs Large MAGUK Scaffold Protein 1; MTORC1: Mechanistic Target of Rapamycin Kinase Complex 1; PP2A: Protein Phosphatase 2 Phosphatase Activator; S6K: Ribosomal Protein S6 Kinase B1; 4E-BP1: Eukaryotic Translation Initiation Factor 4E Binding Protein 1; MAPK: Mitogen-Activated Protein Kinase; B-Raf: B-Raf Proto-Oncogene Serine/Threonine Kinase; PTM: post-translational modifications; HATs: histone acetyltransferases; HDAC6: Histone Deacetylase 6; SF3B: Splicing Factor 3b Subunit; SRPK1: Serine/Arginine-Rich Protein-Specific Kinase 1; SRPK2: Serine/Arginine-Rich Protein-Specific Kinase 2; PRP4: Pre-MRNA Processing Factor 4; SDMA: symmetric arginine demethylation; RMT5: Protein Arginine Methyltransferase 5.

Acknowledgements

This work was supported in part by grants from the National Natural Science Foundation of China (81702919, 81802478), Guangxi Natural Science Foundation (2017GXNSFBA198071, 2018GXNSFBA050042), Guangxi Science and Technology Program Project (AD19245005), the Natural Science Foundation of Hunan Province (No.2020JJ5480) and the Applied Basic Research Programs of Science and Technology Commission Foundation of Shanxi Province (201901D211472).

Authors’ contributions

XZ, QP, LW, XZ and LH collected the related paper and drafted the manuscript. JW and ZQ revised and finalized the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Adami S, Pilarski PM, Bar-Natan M, Stone RM, Griffin JD. Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Curr Cancer Drug Targets. 2013; 13: 735-48.
2. Kalsotra A, Cooper TA. Functional consequences of developmentally regulated alternative splicing, Nat Rev Genet. 2011; 12: 715-29.
3. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A. 2006; 103: 20333-8.
4. Yap K, Lim ZQ, Khandelia P, Friedman B, Makeyev EV. Coordinated regulation of neuronal mRNA steady-state levels through developmentally controlled intron retention. Genes Dev. 2012; 26: 1209-25.
5. Sette C. Alternative splicing programs in prostate cancer. Int J Cell Biol. 2013; 2013: 458727.
6. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res. 2004; 64: 7647-54.
7. Yan C, Hang J, Wan R, Huang M, Wong CC, Shi Y. Structure of a yeast spliceosome at 3.6 Å resolution. Science. 2015; 349: 1182-91.
8. Wan R, Yan C, Bai R, Wang L, Huang M, Wong CC, et al. The 3.8 Å structure of the U4/U6.U5 tri-snRNP: Insights into spliceosome assembly and catalysis. Science. 2016; 351: 466-73.
9. Zhang X, Yan C, Hang J, Finci LL, Lei J, Shi Y. An Atomic Structure of the Human Spliceosome. Cell. 2017; 169: 918-29 e14.
10. Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med. 2012; 18: 472-82.
11. Ma S, SR Proteins: Binders, Regulators, and Connectors of RNA. Mol Cells. 2017; 40: 1-9.
12. Savisaar R, Hurst LD. Purifying Selection on Exonic Splice Enhancers in Intronless Genes. Mol Biol Evol. 2016; 33: 1396-418.
13. Huang Y, Gattoni R, Stevenin J, Stelzl JA. SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol Cell. 2003; 11: 937-43.
14. Li X, Manley JL. Inactivation of the SR protein splicing factorASF/SF2 results in genomic instability. Cell. 2005; 122: 365-78.
15. Li X, Ferri KL, SRP54, SRP40, and hnrNP splicing regulatory factors. Wiley Interdiscip Rev RNA. 2012; 3: 1-12.
16. Manley JL, Krainer AR. A rational nomenclature for serine/arginine-rich protein splicing factors (SR proteins). Genes Dev. 2010; 24: 1073-4.
17. Zahler AM, Neugebauer KM, Stolk JA, Roth MB. Human SR proteins and SR protein-related regulators of a DNA encoded splicing code. Nat Cell Biol. 1995; 13: 402-8.
18. Kamri R, de Stanchina E, Lowe SW, Sinha R, Ma D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007; 14: 185-93.
19. Liu J, Huang B, Xiao Y, Xiong HM, Li J, Feng DQ, et al. Aberrant expression of splicing factors in newly diagnosed acute myeloid leukemia. Oncology. 2012; 35: 335-40.
20. Anszczukow O, Akerman M, Clery A, Wu J, Shen C, Shirole NH, et al. SRFS1-Regulated Alternative Splicing in Breast Cancer. Mol Cell. 2015; 60: 105-17.
21. Jiang L, Huang J, Higgins BW, Hu Z, Xiao Z, Yao X, et al. Genomic Landscape Survey Identifies SRFSF1 as a Key Oncoregulator in Small Cell Lung Cancer. PLoS Genet. 2016; 12: e1005896.
22. Zhou Z, Fu XD. Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma. 2013; 122: 191-207.
23. Howard JM, Sanford JR. The RNAissance family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip Rev RNA. 2015; 6: 93-110.
24. Ge H, Zuo P, Manley JL. Primary structure of the human splicing factorASF reveals similarities with Drosophila regulators. Cell. 1991; 66: 373-82.
25. Krainer AR, Mayeda A, Kozak D, Birns G. Functional expression of cloned human splicing factor SF2: homology to SR proteins, U1 70K, and Drosophila splicing regulators. Cell. 1991; 66: 383-94.
26. Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J. 2009; 415: 17-27.
27. Sahaib M, Hanafi MM, van Wijnen AJ, Azizi P, Abiri R, Ashkani S, et al. Towards understanding pre-mRNA splicing mechanisms and the role of SR proteins. Gene. 2016; 575: 107-19.
28. Cho S, Huang A, Sinha R, Zhong XY, Fu XD, Krainer AR, et al. Interaction between the RNA binding domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein determines early spliceosome assembly. Proc Natl Acad Sci U S A. 2011; 108: 8233-8.
29. Shen M, Mattox W. Activation and repression functions of an SR splicing regulator depend on exonic versus intronic-binding position. Nucleic acids research. 2012; 40: 428-37.
30. Erkelenz S, Mueller WF, Evans MS, Busch A, Schoneweis K, Hertel KJ, et al. Position-dependent splicing activation and repression by SR and hnrNP proteins rely on common mechanisms. RNA. 2013; 19: 96-102.
31. Twyfelds L, Guedyán C, Krays V. Shuttling SR proteins: more than splice factors. FEBS J. 2011; 278: 3246-55.
32. Misteli T, Caceres JF, Spector DL. The dynamics of a pre-mRNA splicing factor in living cells. Nature. 1997; 387: 523-7.
33. Yuryev A, Patturajan M, Litingtung Y, Joshi RV, Gentile C, Gebara M, et al. The C-terminal domain of the largest subunit of RNA polymerase II interacts with a novel set of serine/arginine-rich proteins. Proc Natl Acad Sci U S A. 1996; 93: 6975-80.
34. Das R, Yu J, Zhang Z, Gygi MP, Krainer AR, Gygi SP, et al. SR proteins function in coupling RNP II transcription to pre-mRNA splicing. Mol Cell. 2007; 26: 867-81.
35. Lin S, Coutinho-Manfels G, Wang D, Pandit S, Fu XD. The splicing factor SRSF5 has an active role in transcriptional elongation. Nat Struct Mol Biol. 2008; 15: 819-26.
36. Dai D, Wang H, Zhu L, Jin H, Wang X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2016; 15: 819-26.
37. Zhao W, Qi X, Liu L, Liu Z, Ma S, Wu J. Epigenetic Regulation of m(6)A modification and its emerging regulatory role in mRNA splicing. Science. 2016; 351: 466-73.
38. Yang Y, Sun B-F, Xiao W, Yang X, Sun H-Y, Zhao Y-L, et al. Dynamic m 6 A regulation and its emerging regulatory role in mRNA splicing. Science. 2016; 351: 466-73.
40. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. Cell Res. 2014; 24: 1403-19.

41. Xu Xufan, Shi Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6: 635-45.

42. Chatterjee S, Reddy RD, Pajares MJ, Montuenga LM, Rubio A, Pio R. Identification of alternative splicing events regulated by the oncogenic factor SRSF5 in lung cancer. Cancer Res. 2014; 74: 1105-11.

43. Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti J, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in colorectal cancer. Gut. 2019; 68: 118-29.

44. Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, et al. Reader YTHDC1 Regulates mRNA Splicing. Mol Cell. 2016; 61: 507-19.

45. Zhou X, Wang R, Li X, Yu L, Hua D, Sun C, et al. Splicing factor SRSF1 is upregulated by oncogene SRSF3 in oral squamous cell carcinoma. Int. J. Biol. Sci. 2020, Vol. 16: 2452.
101. Velazquez-Dones A, Hapogian JC, Ma CT, Zhong XY, Zhou H, Ghosh G, et al. Mass spectrometric and kinetic analysis of ASF/SEF phosphorylation by SRPK1 and Cdk/ Cyr. J Biol Chem. 2005; 280: 41761-8.

102. Wu Q, Zhang Y, Zhang L, Yang Y, Tian T, Feng G, et al. SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemoresistivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions. Journal of Cancer. 2013; 4: 727-35.

103. Matoz P, Goncalves O, Jordan P. Targeting the spliced pathway of colorectal cancer with mutation in BRAF. Biochimica et biophysica acta. 2016; 1866: 51-63.

104. Goncalves O, Henriques AF, Pereira JF, Neves Costa A, Moyer MP, Moita LF, et al. Phosphorylation of SRPS1 by SRPK1 regulates alternative splicing of tumor-related Rac1B in colorectal cells. RNA. 2014; 20: 474-82.

105. Pelisch F, Gerez J, Druker J, Schor IE, Munoz MJ, Risso G, et al. The serine/arginine-rich protein SF2/ASF regulates protein sumoylation. Proc Natl Acad Sci U S A. 2010; 107: 16191-24.

106. Choudhary C, Kumar G, Chad G, Niehen ML, Rehman M, Walter HC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009; 325: 834-40.

107. Edmond V, Moisan E, Kehobin S, Matthias P, Brambilla C, Brambilla E, et al. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J. 2011; 30: 510-23.

108. Ezponda T, Pajares MJ, Agorreta J, Echeveste JJ, Lopez-Picazo JM, Torre W, et al. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res. 2010; 16: 4113-25.

109. Bonnal S, Vigevan I, Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 2012; 11: 847-59.

110. Effgenberger KA, Urabe VK, Jurica MS. Modulating splicing with small molecular inhibitors of the spliceosome. Wiley Interdiscip Rev RNA. 2017; 7: 57-68.

111. Surget S, Khoury MP, Boudon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2013; 7: 49-57.

112. Paronetto MP, Passacantillli I, Sette C. Alternative splicing and cell survival: from tissue homeostasis to disease. Cell Death Differ. 2016; 23: 1919-29.

113. Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, et al. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as an anti-cancer strategy. Oncotarget. 2017; 8: 9174-88.

114. Lee SC, Abdely-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016; 22: 976-86.

115. Agrawal AA, Yu L, Smith PG, Buonamici S. Targeting splicing abnormalities as a therapeutic vulnerability in MYC-driven cancer. Nature. 2015; 525: 384-8.

116. Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al. Targeting splicing abnormalities as a therapeutic vulnerability in MYC-driven cancer. Nature. 2015; 525: 384-8.

117. Lee SC, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016; 22: 976-86.

118. Sheng J, Zhao Q, Zhao J, Zhang W, Sun Y, Qin P, et al. SRSF1 modulates hairpin RNA screen of genes associated with multidrug resistance identifies agents that enhance paclitaxel activity in breast cancer cells. Breast cancer research : BCR. 2010; 12: R41.

119. Vu LP, Cheng Y, Kharas MG. The Biology of m(6)A RNA Methylation in Glioma in Normoxic and Hypoxic Conditions. Journal of Cancer. 2013; 4: 1900-4.

120. Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, et al. The spliceosome is a therapeutic vulnerability in MVD-driven cancer. Nature. 2015; 525: 384-8.